AngioLab, Inc. Logo

AngioLab, Inc.

Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.

251280 | KO

Overview

Corporate Details

ISIN(s):
KR7251280004
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노3로 65, 대전광역시

Description

AngioLab, Inc. is a biotechnology company specializing in the discovery and development of angiogenesis inhibitors. The company develops pharmaceuticals and health functional foods to treat diseases associated with the abnormal growth of blood vessels. Its pipeline includes drug candidates targeting conditions such as age-related macular degeneration (AMD), with some candidates having undergone Phase II clinical trials. AngioLab has also developed Ob-X, a functional food ingredient based on its anti-angiogenic research platform.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-01-30 00:00
[기재정정]기타주요경영사항(자율공시)(전환우선주의 보통주 전환청구)
Korean 11.3 KB
2024-01-15 00:00
주식등의대량보유상황보고서(약식)
Korean 80.7 KB
2024-01-12 00:00
기타주요경영사항(자율공시)(전환우선주의 보통주 전환청구)
Korean 7.7 KB
2023-12-13 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2023-11-29 00:00
기타주요경영사항(자율공시)(전환우선주의 보통주 전환청구)
Korean 8.0 KB
2023-11-28 00:00
주식등의대량보유상황보고서(약식)
Korean 66.4 KB
2023-10-31 00:00
기타주요경영사항(자율공시)(전환우선주의 보통주 전환 청구)
Korean 7.7 KB
2023-10-26 00:00
기업설명회(IR)개최결과
Korean 6.7 KB
2023-06-22 00:00
기업설명회(IR)개최결과
Korean 6.7 KB
2023-04-04 00:00
주식등의대량보유상황보고서(일반)
Korean 143.7 KB
2023-03-30 00:00
정기주주총회결과
Korean 22.4 KB
2023-03-30 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.2 KB
2023-03-30 00:00
주식매수선택권부여에관한신고
Korean 14.1 KB
2023-03-22 00:00
사업보고서 (2022.12)
Korean 1.1 MB
2023-03-20 00:00
감사보고서제출
Korean 9.6 KB

Automate Your Workflow. Get a real-time feed of all AngioLab, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AngioLab, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AngioLab, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030
Aptahem AB Logo
A clinical-stage biotech developing aptamer-based drugs for life-threatening conditions.
Sweden
APTA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.